- Phase 2 study is part of the collaboration between
Curasight and Curium announced earlier this year - Appointment of clinical CRO marks further step in progress in development of uTRACE as a potential new diagnostic solution for prostate cancer
The Phase 2 study is an important part of the agreement between Curasight and Curium, for the manufacture and commercialization of uTRACE in prostate cancer, announced earlier this year on May 1 st 2023.
"We are very pleased to be working with the German headquartered clinical research organization ABX-CRO, a company with proven experience in the very specialized field of conducting international diagnostic and therapeutic trials with radiopharmaceutical agents. We believe ABX-CRO is the optimal partner to secure the efficient and effective execution of this trial, which is an important element of our collaboration with Curium for uTRACE in prostate cancer" said
"We are delighted to partne with
About the Phase 2 trial with uTRACE in prostate cancer
The primary objective of this phase 2 trial is to investigate
The trial will be conducted in two parts, with the first part of the trial conducted at three different University hospitals in
About the uPAR diagnostic platform
The uTRACE® platform is part of Curasights uPAR theranostic solution, made up of its uTRACE® diagnostic technology and its uTREAT® targeted treatment technology. In prostate cancer, uTRACE® is presently developed for diagnostic purposes only.
About ABX-CRO Advanced Pharmaceutical Services
ABX-CRO is a German based clinical research organization (CRO) specialized in nuclear medicine and with strong focus in oncology, neuroscience and imaging indications, and with experience in investigations of prostate imaging agents.
About ABX-CRO Advanced Pharmaceutical Services
ABX-CRO is a German based clinical research organization (CRO) specialized in nuclear medicine and with strong focus in oncology, neuroscience and imaging indications, and with experience in investigations of prostate imaging agents.
For more information regarding
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
https://news.cision.com/curasight/r/curasight-a-s-appoints-cro-to-run-phase-2-study-with-utrace--in-prostate-cancer,c3893226
https://mb.cision.com/Main/19744/3893226/2492407.pdf
(c) 2023 Cision. All rights reserved., source